Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity
Authors:
- Joel M. GuthridgeJGJoel M. Guthridge
- Abigail CogmanACAbigail Cogman
- Joan T. MerrillJMJoan T. Merrill
- Susan MacwanaSMSusan Macwana
- Krista M. BeanKBKrista M. Bean
- Tiny PoweTPTiny Powe
- Virginia RobertsVRVirginia Roberts
- Judith A. JamesJJJudith A. James
- Eliza F. ChakravartyECEliza F. Chakravarty
Open Access
- 15 September 2013
- journal article
- clinical trial
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 40 (11) , 1875-1880
Abstract
Objective.: Patients with systemic lupus erythematosus (SLE) are at increased risk of herpes zoster (HZ). Although a vaccine for HZ has been approved by the US Food and Drug Administration, its use in immunocompromised individuals remains controversial because it is a live-attenuated virus vaccine. We performed a pilot study of the immunogenicity of the HZ vaccine (Zostavax) in patients with SLE.Methods.: Ten patients with SLE and 10 control subjects ≥ age 50 years participated in this open-label vaccination study. All were seropositive for varicella zoster virus (VZV). Patients with SLE were excluded for SLE Disease Activity Index (SLEDAI) > 4, or use of mycophenolate mofetil, cyclophosphamide, biologics, or > 10 mg prednisone daily. Followup visits occurred at 2, 6, and 12 weeks. Clinical outcomes included the development of adverse events, particularly HZ or vesicular lesions, and SLE flare. Immunogenicity was assessed with VZV-specific interferon-γ-producing enzyme-linked immunospot (ELISPOT) assays and with antibody concentrations.Results.: All subjects were women. Patients with SLE were slightly older than controls (60.5 vs 55.3 yrs, p < 0.05). Median baseline SLEDAI was 0 (range 0–2) for patients with SLE. No episodes of HZ, vesicular rash, serious adverse events, or SLE flares occurred. Three injection site reactions occurred in each group: mild erythema or tenderness. The proportion of subjects with a > 50% increase in ELISPOT results following vaccination was comparable between both groups, although absolute SLE responses were lower than controls. Antibody titers increased only among controls following vaccination (p < 0.05).Conclusion.: The HZ vaccination yielded a measurable immune response in this cohort of patients with mild SLE taking mild-moderate immunosuppressive medications. No herpetiform lesions or SLE flares were seen in this small cohort of patients.ClinicalTrials.govID:NCT01474720.Keywords
This publication has 22 references indexed in Scilit:
- Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort studyInfection, 2011
- A Prospective Study of the Herpes Zoster Severity of IllnessThe Clinical Journal of Pain, 2010
- Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus ErythematosusJCR: Journal of Clinical Rheumatology, 2010
- Viral infection and reactivation in autoimmune diseaseArthritis & Rheumatism, 2008
- Varicella‐Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster VaccineThe Journal of Infectious Diseases, 2008
- Herpes Zoster in Juvenile-Onset Systemic Lupus ErythematosusThe Pediatric Infectious Disease Journal, 2006
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Herpes zoster in Japanese patients with systemic lupus erythematosusClinical and Experimental Dermatology, 1999
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982